# A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma

> **NCT01698801** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 26 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** dexamethasone

## Key facts

- **NCT ID:** NCT01698801
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-01
- **Primary completion:** 2013-11-26
- **Final completion:** 2018-06-26
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2018-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01698801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01698801, "A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01698801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*